about
Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer typesDiscovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencingGenome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphomaGenetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypesGenome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLLA meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locusChemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cOfatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.Active idiotypic vaccination versus control immunotherapy for follicular lymphomaA polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphomaGenetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphomaA systematic review of validated methods for identifying lymphoma using administrative data.Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region.Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States.A genome-wide association study of marginal zone lymphoma shows association to the HLA region.Identification of candidate B-lymphoma genes by cross-species gene expression profiling.Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin LymphomaElevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports.Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphomaRituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile.Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphomaThe oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32.Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma.Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular EpidemiOutcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.Follicular lymphoma following liver transplantation: report of a unique case with review of the literature.Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaPretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control studyIntravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy
P50
Q24170413-45CB4106-7600-4FD2-887D-13B2BF71980FQ24612248-450A012E-8DC7-4307-9D36-E1FB8B7860EDQ28248768-CA914209-A6A8-432C-9EF0-4C57D03DA6DEQ28393571-CDF0000A-1155-4A99-B170-A793380AAE85Q28943377-65C997C5-67FA-4A1B-9B09-CBC3603144B9Q28943487-FE8FC2BF-FC1F-4B6D-9D03-385D0A7B1350Q30408922-DA40F68F-1307-4991-B1E4-E274CC3AEC26Q33400078-4625AFDF-2B8C-4D26-925E-83FF5358138BQ33598099-41066850-CC07-406D-9979-CD261A765992Q33691505-CB2DFD4A-6305-4F12-A2B5-25E7E19F8463Q34007430-B7BE709F-08DD-41B6-88E1-EC973FAA9F89Q34062500-4209D48C-7969-4F81-AE30-435E0231344FQ34133911-5E3860F6-7463-4015-8980-3075B0F38199Q34193968-74809B4D-C737-45FC-BA9F-E72394B2C7C4Q34288685-F6A4F78E-15A3-495F-96E3-309407297311Q34334943-5EC1CAE0-D883-4DB7-BF9F-173339986DDBQ34402503-8D13CD6F-4E21-40EC-9435-5A694B5018A2Q34699650-4D0E6CCA-4558-4CB5-B940-EB159F2C4BF6Q34881099-72D6F2CE-0EA2-4A96-8B86-22102079274FQ35018604-51F4E707-8920-4CFC-B215-587AE8BE5A10Q35038832-DBC73EBF-F09B-477B-92E3-9C7778D5F1AAQ35056309-1EC7A2D9-77E5-4D98-B529-2670BCEFF356Q35064885-DB9198C8-6948-49BF-A2AF-87DEE8FF3D70Q35185207-9BD2F88D-BA7C-4A64-B104-E2DCE6CE01B7Q35230227-63D31917-8DD0-4E9F-B970-36338ABFB27EQ35247997-6F6163DB-FF5E-407D-B664-CBBA84725CADQ35483564-9A5FF23B-61FF-46DB-A868-98771E343E9BQ35607281-810EA65A-398C-4D0A-BD46-D69B1CF21D84Q35669222-2E03CC29-936F-4715-B835-5356E75CA30CQ35832407-C9863E23-82C8-43F7-8D50-7C0DDCC1AD6FQ35842024-642EB6D2-DCF1-409E-B5AB-22347179CFA8Q35931755-BEAA3280-5A9D-407B-A31F-85A0A33A0D63Q35979057-A4B9302E-49EC-40F1-B1B6-4050E079E551Q35986609-74248CA3-5C4E-4206-95E0-B9CB63112EF4Q35994617-F6181FC1-5A4F-4E0C-B0C0-089CB59A9AEDQ36022544-37FDC99D-FE88-4BB4-B499-2376B46D8C40Q36195016-ECBC0C46-3143-4CEA-A8EE-C187E0BC007CQ36222910-CF392572-4183-4BB5-8B97-1D3754462794Q36354265-1E7F7C72-C33E-4B3D-A3F5-807C014F7D3CQ36463391-9586C0E5-BBA2-4BC5-BC6A-D615401461E2
P50
description
researcher ORCID ID = 0000-0001-5084-0698
@en
wetenschapper
@nl
name
Brian K Link
@ast
Brian K Link
@en
Brian K Link
@es
Brian K Link
@nl
type
label
Brian K Link
@ast
Brian K Link
@en
Brian K Link
@es
Brian K Link
@nl
altLabel
Brian Link
@en
Link BK
@en
prefLabel
Brian K Link
@ast
Brian K Link
@en
Brian K Link
@es
Brian K Link
@nl
P106
P1153
7102802933
P21
P31
P496
0000-0001-5084-0698